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ABSTRACT
Background. [99mTc]Tilmanocept is a CD206 receptor-
targeted radiopharmaceutical designed for sentinel lymph
node (SLN) identification. Two nearly identical nonran-
domized phase III trials compared [99mTc]tilmanocept to
vital blue dye.
Methods. Patients received [99mTc]tilmanocept and blue
dye. SLNs identified intraoperatively as radioactive and/or
blue were excised and histologically examined. The pri-
mary end point, concordance, was the proportion of blue
nodes detected by [99mTc]tilmanocept; 90 % concordance
was the prespecified minimum concordance level. Reverse
concordance, the proportion of radioactive nodes detected
by blue dye, was also calculated. The prospective statistical
plan combined the data from both trials.
Results. Fifteen centers contributed 154 melanoma
patients who were injected with both agents and were
intraoperatively evaluated. Intraoperatively, 232 of 235 blue
nodes were detected by [99mTc]tilmanocept, for 98.7 %
concordance (p \ 0.001). [99mTc]Tilmanocept detected 364
nodes, for 63.7 % reverse concordance (232 of 364 nodes).
[99mTc]Tilmanocept detected at least one node in more
patients (n = 150) than blue dye (n = 138, p = 0.002). In
135 of 138 patients with at least one blue node, all blue nodes
were radioactive. Melanoma was identified in the SLNs of
22.1 % of patients; all 45 melanoma-positive SLNs were
detected by [99mTc]tilmanocept, whereas blue dye detected
only 36 (80 %) of 45 (p = 0.004). No positive SLNs were
detected exclusively by blue dye. Four of 34 node-positive
patients were identified only by [99mTc]tilmanocept, so 4
(2.6 %) of 154 patients were correctly staged only by
[99mTc]tilmanocept. No serious adverse events were attrib-
uted to [99mTc]tilmanocept.
Conclusions. [99mTc]Tilmanocept met the prespecified
concordance primary end point, identifying 98.7 % of blue
nodes. It identified more SLNs in more patients, and
identified more melanoma-containing nodes than blue dye.
The introduction of sentinel lymph node (SLN) biopsy
revolutionized the surgical management of cutaneous
melanoma, providing a minimally invasive means to stage
clinically negative regional nodes and identify patients
with microscopic nodal involvement for early therapeutic
intervention.1,2 Despite its widespread use, the technique
of performing SLN biopsy remains surprisingly nonstan-
dardized. The original standard for defining a first-echelon
Preliminary results of these two phase III trials were presented at the
2011 American Society of Clinical Oncology Annual Meeting
(Chicago, IL), abstract LBA8526, and at the 2011 Society of Nuclear
Medicine Annual Meeting (San Antonio, TX), abstract 599.
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or ‘‘sentinel’’ node draining a primary cutaneous melanoma
was the visual identification of blue color in the node after
injection of a vital blue dye (initially isosulfan blue or
Patent Blue V) at the primary tumor site.3 The limited
availability of these vital blue dyes led some to adopt
methylene blue dye for lymphatic mapping, despite con-
flicting data on its comparability and safety.4,5 Most
surgeons also adopted radiolabeled colloid to detect the
location of SLNs preoperatively via lymphoscintigraphy
and intraoperatively using a hand-held gamma radiation
detecting probe in conjunction with blue dye visualization
of the SLN. Several different colloids with varying prop-
erties are used around the world, with different methods of
preparation (such as filtration to limit the size of the col-
loidal particles injected).6–9 A number of surgeons do not
use blue dye at all for melanoma lymphatic mapping,
preferring to rely exclusively on the radiolabeled colloid.10
The ideal radiopharmaceutical for melanoma lymphatic
mapping would have several favorable properties: it would
be standardized and require minimal preparation or modi-
fication before injection; it would be nontoxic and
relatively painless, eliminating the need to infiltrate or
include local anesthetics that could influence the rate of
lymphatic uptake; it would be promptly taken up by the
lymphatics and quickly transported to the first-echelon
nodes; it would accumulate in the first-echelon nodes in
high amounts, providing good contrast to background
counts in the nodal basin and to the residual counts at the
primary site (i.e., minimizing shine-through and maxi-
mizing step-down); and it would reside in the first-echelon
nodes with minimal pass-through to second-echelon (non-
sentinel) nodes. Obviously, to the degree that vital blue
dyes are considered the gold standard for SLN identifica-
tion, this ideal radiotracer should colocalize in those nodes
that were blue stained. The ultimate goal of SLN biopsy,
however, is to effectively identify tumor-containing nodes;
an ideal radiotracer should identify a very high percentage
of pathology-positive nodes, whether stained blue or not.
To date, no available radiolabeled colloid meets the
above criteria of the ideal radiopharmaceutical SLN map-
ping agent, and indeed in the United States there is no
radiopharmaceutical currently approved by the US Food
and Drug Administration (FDA) specifically for the pur-
pose of SLN identification in melanoma. Recently, the US
FDA granted approval to technetium (99mTc) sulfur colloid
injection (SCI; Pharmalucence, Billerica, MA) for SLN
identification in breast cancer, based entirely on retro-
spective data showing a high degree of concordance
between nodes stained blue by blue dye and those identi-
fied as radioactive above baseline (i.e., ‘‘hot’’) with SCI,
along with a high rate of identification of tumor-positive
nodes as hot.11 Such retrospective data are clearly limited
by varying definitions of the threshold for considering a
node to be hot, as well as the many differences in dose,
formulation, and preparation inherent when SCI is used at
different institutions. These limitations notwithstanding,
the US FDA is expected to consider whether to approve
SCI for SLN identification in cutaneous melanoma based
on similar methodology in the near future.
[99mTc]Tilmanocept (Fig. 1) is an engineered radiophar-
maceutical specifically designed for lymphoscintigraphic and
intraoperative SLN detection, created with the goal of
attaining as many of the properties of the ideal radiotracer as
possible.12 Tilmanocept is a fully standardized reagent
requiring little or no manipulation before injection. Its mul-
tiple diethylene-triamine-pentaacetic acid (DTPA) moieties
chelate and bind tightly to 99mTc, while its multiple mannose
moieties serve as ligands for multivalent binding to mannose
receptors (CD206) expressed on the surfaces of reticuloen-
dothelial cells resident in lymph nodes.13,14 Preclinical studies
and phases I and II clinical trials have provided evidence that
[99mTc]tilmanocept fulfills many of the desired characteristics
FIG. 1 Chemical structure of [99mTc]tilmanocept. [99mTc]Tilmano-
cept is composed of a dextran backbone (black) to which are attached
multiple units of mannose (green) and DTPA (blue). The mannose
units provide a molecular mechanism by which [99mTc]tilmanocept
avidly binds to a receptor specific to reticuloendothelial cells
(CD206), and the DTPA units provide a highly stable means to
radiolabel tilmanocept with 99mtechnetium (red). The molecular
weight of [99mTc]tilmanocept is approximately 19,000 g/mol; the
molecular diameter is 7.1 nm (adapted from Wallace et al.16)
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of the ideal radiotracer for SLN identification.12,15–19 Its
chemical structure and relatively small size (molecular
weight & 19,000 Da, diameter 7.1 nm) enable [99mTc]til-
manocept to exit the injection site rapidly and quickly
accumulate in first-echelon nodes. Within lymph nodes,
interactions between [99mTc]tilmanocept’s mannose moieties
and CD206 enable avid binding to the target receptor and
retention for up to 30 h (Fig. 2), potentially limiting transit to
second-echelon nodes.20 In phase I trials involving small
numbers of melanoma and breast cancer patients, [99mTc]til-
manocept showed favorable properties when directly
compared to patients injected with sulfur colloid in the same
study.16,17 In a phase II trial, 49 melanoma and 31 breast
cancer patients underwent SLN biopsy using [99mTc]tilma-
nocept with or without blue dye.19 At least one SLN was
identified by [99mTc]tilmanocept in 96.2 % of 78 evaluable
patients, including 46 of the melanoma patients, with an
average of 2.3 hot nodes identified per melanoma
patient. Eighteen of 19 nodes found to contain melanoma and
8 of 9 nodes with breast cancer were identified by
[99mTc]tilmanocept. No patients experienced adverse events
the investigators considered probably or definitely related to
[99mTc]tilmanocept.19
An ultimate assessment of the suitability of [99mTc]til-
manocept for use in melanoma SLN identification,
however, requires larger patient numbers in a phase III trial
setting. This report describes results of two phase III trials
with basically identical designs: open-label, nonrandom-
ized trials in which clinically node-negative patients
received both [99mTc]tilmanocept and blue dye for SLN
identification. The goal of these trials, which included both
melanoma and breast cancer patients, was to evaluate the
concordance (colocalization within the same lymph node)
of [99mTc]tilmanocept and vital blue dye, while also
determining the safety profile of [99mTc]tilmanocept and
how often [99mTc]tilmanocept identified tumor-containing
nodes that were not blue-stained. This trial design was not
intended to compare [99mTc]tilmanocept to any other ra-
diocolloid. We describe the summed results for melanoma
patients enrolled onto these two trials.
METHODS
Study Design
Two phase III trials were performed on patients without
preoperative clinical evidence of nodal metastases under-
going clinically indicated SLN biopsy for cutaneous
melanoma. Evaluating concordance of [99mTc]tilmanocept
with blue dye was the primary end point of both studies.
Both were prospective, open-label, nonrandomized, within-
patient trials in which all patients were to receive both
[99mTc]tilmanocept and a vital blue dye (isosulfan blue
[Lymphazurin] or Patent Blue V). Nine sites enrolled
patients June 2008–June 2009 in the first trial, while six
sites enrolled patients July 2010–April 2011 in the second.
Other than the sites involved and the number of patients per
site allowed, the two studies were virtually identical. This
report describes results obtained from the melanoma
patients who participated in these two trials.
Enrollment criteria included the histologically con-
firmed presence of cutaneous melanoma C0.76 mm with a
surgical treatment plan including SLN biopsy. Table 1 lists
complete eligibility criteria. Patients received a fixed dose
of 50 lg of [99mTc]tilmanocept (*2.7 nmol) administered
by intradermal injection. For surgery on the day of the
injection, patients received *0.5 mCi of 99mTc, while
next-day surgery patients received *1.0–2.0 mCi (timing
of injection was at the surgeon’s discretion). Blue dye was
injected intradermally after [99mTc]tilmanocept, at the time
of surgery.
Criteria for Intraoperative Identification of SLNs
Three criteria were utilized for intraoperative identifi-
cation of SLNs. Briefly, the first criterion was in vivo
visualization of blue dye in a node and/or its afferent
lymphatic channel. All such nodes were designated as blue
and removed. The second criterion was based on radioac-
tivity; background counts (using either one 10-s count or
FIG. 2 Preoperative lymphoscintigraphy with [99mTc]tilmanocept.
Images were obtained over 24 h in a 72-year-old melanoma patient
undergoing SLN biopsy for a 0.95-mm nonulcerated melanoma. The
patient received four intradermal injections, each consisting of
0.49 mCi of [99mTc]tilmanocept, at the primary site on the left
forearm (first image, top row) and one axillary SLN was visualized at
20 min (second through fourth images, top row), along with activity
in lymphatic channels of the upper arm seen superior and distal to the
SLN. The same SLN visualized at 20 min was observed at 24 h
(bottom row). Intraoperatively, approximately 1 h after the final
image was obtained, the tissue background 10-second count was 50
(3r = 71, see text) and a single blue axillary node with 10-s counts of
1,521 was found corresponding to the SLN on the images. This node
had no histologic evidence of melanoma
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the average of three 2-s counts), were measured directly on
the patient C20 cm from the primary site and nodes were
interrogated using a Neoprobe gamma detector before (in
vivo) and after excision (ex vivo). To qualify as radioactive
(hot), the in vivo counts in the node had to (1) exceed the
background count plus three times the standard deviation
of the background (termed the 3r rule; corresponding to
the 99.7 % confidence limits; Fig. 3) and (2) average at
least 50 (for three 2-s counts) or exceed 250 (for one 10-s
count). The third criterion for intraoperative identification
of SLNs was any palpably enlarged or abnormal node. All
excised nodes underwent histological evaluation with
hematoxylin and eosin and immunohistochemistry using S-
100 and HMB-45 and/or MART-1/Melan-A antibodies.
Statistical Plan
The statistical plan defined the population for assessing
concordance as all enrolled patients who received both
[99mTc]tilmanocept and blue dye and who had at least one
blue-stained histologically confirmed lymph node. Drug
safety was analyzed on all enrolled patients who received
[99mTc]tilmanocept, whether or not they received blue dye.
The primary efficacy end point, the per lymph node con-
cordance of [99mTc]tilmanocept with blue dye, was defined
as the number of blue-stained nodes that were detected by
[99mTc]tilmanocept, divided by the number of blue-stained
lymph nodes. Concordance was tested in a pooled analysis
with the alternative hypothesis that [99mTc]tilmanocept
would be considered concordant to blue dye if [90 %
of blue nodes were radioactive per the above definition.
A 95 % two-sided exact binomial confidence interval (CI)
for concordance was calculated; a two-sided p value of
B0.05 indicated that the null hypothesis was rejected. A
secondary end point was the per patient concordance rate,
defined as the percentage of patients for whom all nodes
detected by blue dye were detected by [99mTc]tilmanocept.
Another secondary end point, reverse concordance, evalu-
ated the proportion of all nodes detected by [99mTc]
tilmanocept that were also blue. The proportions of path-
ologically positive lymph nodes that were blue and/or
radioactive were compared using McNemar’s exact test.
Study Oversight and Role of the Sponsor
The protocols, patient instructions, and informed con-
sent documentation were approved by the US FDA, the
Western Institutional Review Board, and the institutional
review boards of each enrolling institution. These studies
complied with all provisions of the Declaration of Helsinki
and US laws requiring registration and updates via
ClinicalTrials.gov (trial numbers NCT00671918 and
NCT01106040). All participants gave voluntary written
informed consent. The trial was designed by the sponsor,
Navidea Biopharmaceuticals, who supplied tilmanocept
cold kits for radiolabeling to each study site. Data were
analyzed independently by STATKING Clinical Services
in collaboration with the authors, who vouch for the
completeness and accuracy of the data and analyses. An
initial draft of this article was prepared by the first author
and reviewed by Navidea medical personnel, independent
statistical reviewers, and auditors. All authors contributed
TABLE 1 Study enrollment criteria
Inclusion criteria
Confirmed presence of cutaneous melanoma with clinically negative nodes
Candidate for surgical intervention, with sentinel node biopsy part of the surgical plan
At least 18 years of age
ECOG performance status of 0–2
If female, either negative pregnancy test within 72 h before [99mTc]tilmanocept administration or surgically sterilized or postmenopausal for
at least 1 year before study entry
Exclusion criteria
Pregnancy or lactation
Clinical or radiological evidence of metastatic cancer, including palpably abnormal or enlarged lymph nodes
Known hypersensitivity to isosulfan blue or Patent Blue V
Participation in another investigational drug study
Melanoma with a Breslow depth of \0.76 mm
Prior diagnosis of an invasive melanoma occurring on the same body region or potentially draining to the same nodal basin
Truncal or extremity primary melanoma and a prior breast cancer potentially draining to the same axillary nodal basin
Preoperative chemotherapy, immunotherapy, or radiotherapy
Node basin surgery of any type or radiation to the nodal basin(s) potentially draining the primary melanoma
Prior wide excision ([1 cm in dimension) or complex reconstruction for the primary melanoma
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A total of 170 melanoma patients were enrolled in the
two phase III trials, of whom 14 were not injected with
[99mTc]tilmanocept because of withdrawal of consent or
trial conclusion before scheduled surgery. The demo-
graphic characteristics of the 156 enrolled patients with
melanoma who satisfied the inclusion and exclusion crite-
ria and were injected with [99mTc]tilmanocept are given in
Table 2. There was a predominance of male patients
(61.5 %), and most patients (68.6 %) had intermediate-
thickness melanomas (1.01–4.00 mm in thickness, stage
T2 or T3). Two patients were injected with [99mTc]tilma-
nocept but were not injected with blue dye; these patients
were evaluable for safety of [99mTc]tilmanocept but not for
concordance.
Intraoperative Node Identification
In all, 154 patients injected with both [99mTc]tilmano-
cept and blue dye underwent surgery for evaluation of their
sentinel nodes, of whom 138 patients (89.6 %) had at least
one blue node and 150 patients (97.4 %) had at least one
radioactive node. The observation that [99mTc]tilmanocept
detected a node in more patients than blue dye was sta-
tistically significant (p = 0.002). There were 379 lymph
nodes excised; 235 were blue and 364 were radioactive
(Fig. 4a). The 138 patients with at least one blue node had
a mean of 1.7 blue nodes detected per patient. The 150
patients with at least one radioactive node had a mean of
2.4 radioactive nodes detected per patient. Three patients
did not have a lymph node identified intraoperatively by
either [99mTc]tilmanocept or blue dye: one patient exhib-
ited multiple subclavian and retrosternal hot spots upon
lymphoscintigraphy, but as a result of their location, the
investigator elected not to excise the nodes, and two
patients had two nodes removed that were neither hot per
the protocol definition nor blue.
A 
In vivo lymph node counts must be > 
mean normal tissue background count + 
[3x (mean normal tissue background count)] 
AND 
>50 per 2 seconds or >250 per 10 seconds 
Note: mean tissue background and in vivo 
lymph node counts are EITHER one 10-second 
count OR the average of three 2-second counts. 
B 
Example (all 10-second counts): 
Normal tissue background count = 47 
3σ = 47 + (3 x 47) = 67.57
LN01 (blue) in vivo count = 66,952
LN02 (blue) in vivo count = 16,829
LN03 (blue) in vivo count =   2,229
LN04 (no blue) in vivo count = 846 
Compared to normal tissue background, all 
nodes are >3σ and all are >250, so all are 
considered “hot” per protocol definition. 
C
FIG. 3 The 3r rule. a The equation for determining whether the in
vivo radioactive counts in a lymph node are estimated to be at least
three standard deviations above the normal tissue background count.
b Example of 3r calculation for a protocol patient with four SLNs
identified intraoperatively. All in vivo node counts were greater than
the 3r value, and all in vivo counts were [250. All were therefore
considered hot per the protocol definition. c Schematic of injections
of vital blue dye (blue syringe) and [99mTc]tilmanocept (gold syringe)
intradermally at the primary tumor site (brown circle) with lymphatic
mapping with a handheld gamma detection probe. In this example,
nodes 1 through 3 are shown as hot and blue (i.e., per lymph node
concordance 3/3 = 100 %; per patient concordance = yes), while
node 4 is only hot (i.e., reverse concordance 3/4 = 75 %)
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Concordance of [99mTc]Tilmanocept and Vital Blue
Dye
The primary study end point was the concordance
between lymph nodes identified as radioactive with
[99mTc]tilmanocept and lymph nodes identified as blue
with vital blue dye. There were 235 blue lymph nodes
identified; of these, 232 (98.7 %, 95 % CI 96.3–99.7) were
also radioactive (Fig. 4b). This rate of per lymph node
concordance was statistically significant (p \ 0.001), con-
vincingly rejecting the null hypothesis of B90 %
concordance. For the 138 patients with at least one blue
node, 135 patients had all of their blue nodes also radio-
active, for a per patient concordance rate of 97.8 % (95 %
CI 93.8–99.5, p \ 0.001, Fig. 4c).
Reverse concordance was defined as the percentage of
radioactive lymph nodes that were also blue. There were
364 radioactive lymph nodes identified; of these, only 232
(63.7 %, 95 % CI 58.6–68.7) were also blue (Fig. 4d).
Similarly, in only 76 of 150 patients with at least one
radioactive node (50.7 %) were all the radioactive nodes
also blue.
Pathologic Findings
Among the 154 melanoma patients who were injected
with both [99mTc]tilmanocept and blue dye, there were a
total of 45 tumor-containing nodes in 34 patients (22.1 %
SLN positivity rate). [99mTc]Tilmanocept detected all of
these tumor-positive lymph nodes (Fig. 4e). Conversely,
blue dye identified only 36 of the 45 positive nodes (80 %),
missing an involved node in nine patients (26.5 % of node-
positive patients). The difference between the rates of
tumor-positive radioactive and blue lymph nodes was sta-
tistically significant (p = 0.004). Thus, [99mTc]tilmanocept
exhibited a higher detection rate for melanoma-containing
SLNs than blue dye. Overall, 4 of 154 patients (2.6 %)
were staged correctly only by [99mTc]tilmanocept; no
patients were upstaged by blue dye findings alone.
Adverse Events
There were no patient deaths reported on either trial.
There were no immediate or delayed hypersensitivity
reactions to [99mTc]tilmanocept. A total of 45 adverse
events occurred in 29 of the 156 melanoma patients
receiving [99mTc]tilmanocept. Ten serious adverse events
were reported from nine patients, none of which were
deemed by the investigator as probably or definitely related
to [99mTc]tilmanocept (two cases of cellulitis, and one case
of each of nausea, vomiting, seroma, syncope, asthma,
bradycardia, tachycardia and myocardial infarction). The
most common adverse events of any severity were cellulitis
(seven patients), incision site pain (four patients), nausea
(three patients), and seroma (three patients); most adverse
events were mild or moderate in severity.
DISCUSSION
Sentinel node biopsy is widely accepted worldwide as
an important part of the management of clinically localized
cutaneous melanoma.2,21 Despite this worldwide accep-
tance, there is surprisingly little standardization in the
technique, with a variety of different radiocolloids and vital
blue dyes being used. Although isosulfan blue and Patent
Blue V dyes remain the gold standard vital dyes for iden-
tifying SLNs, not all surgeons use them.4,10 Radiocolloids
are almost universally used in melanoma, but there is no
agreement about which colloid to use and whether to filter
it before use to restrict the particle size. The inescapable
conclusion is that the ideal radiopharmaceutical for mela-
noma lymphatic mapping has not yet been established.
[99mTc]Tilmanocept was developed specifically for SLN
identification and has shown favorable results in phase I
and II testing in melanoma and breast cancer.12,16–20 These
results led to the conduct of two phase III nonrandomized













White 154 (98.7 %)




Non-Hispanic 151 (96.8 %)
Hispanic 1 (0.6 %)
Unknown 4 (2.6 %)
Tumor stage, n (%)
T1 29 (18.6 %)
T2 72 (46.2 %)
T3 35 (22.4 %)
T4 20 (12.8 %)
Includes two patients who never received vital blue dye and who are
excluded from concordance analyses
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Blue and hot nodes = 232
Hot only nodes = 132
Neither blue nor hot = 12
Blue only nodes = 3
Phase III Melanoma
Lymph node distribution
Concordance (blue and hot) = 98.7%
Non-concordance (blue only) = 1.3%
P < 0.001
Phase III Melanoma




Reverse concordance (hot and blue) = 63.7%
Non-reverse concordance  (hot only) = 36.3%
Phase III Melanoma
Lymph node reverse concordance
Blue and hot nodes = 36
Hot only nodes = 9




Concordance (all blue and hot) = 97.8%










FIG. 4 Distribution of excised
lymph nodes and concordance of
[99mTc]tilmanocept with vital
blue dye. a Lymph node
distribution, based on a total of
379 excised lymph nodes. Twelve
lymph nodes removed from nine
patients were not blue and did not
meet the protocol definition for
radioactivity above background;
none contained melanoma. b Per
lymph node concordance, based
on a total of 235 blue lymph
nodes. The statistical threshold
for concordance was
prospectively set as 90 % of blue
nodes would be hot. (In b and c,
the red line marks the 90 %
concordance threshold.) c Per
patient concordance, based on
138 patients with at least one blue
lymph node. d Per lymph node
reverse concordance, based on a
total of 364 hot nodes. Only 232
(63.7 %) were also blue. e
Tumor-positive lymph node
distribution, based on 45 lymph
nodes found to contain melanoma
by routine histology and/or
immunohistochemistry. No
tumor-positive nodes were blue
but not hot
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trials evaluating [99mTc]tilmanocept in patients with mel-
anoma or breast cancer undergoing clinically indicated
SLN biopsy with either isosulfan blue or Patent Blue V
dye. The primary end point of these trials was to establish
the degree of concordance between blue dye and
[99mTc]tilmanocept; specifically, the trials were powered to
determine whether more than 90 % of blue nodes were also
radioactive. In 235 blue lymph nodes from 154 melanoma
patients, 232 (98.7 %) were radioactive per the protocol
definition. This result established with a high degree of
statistical probability that [99mTc]tilmanocept is in fact
concordant with vital blue dye above the prespecified 90 %
concordance level. Similar results were seen for patients
with breast cancer; these results will be published
separately.
In addition to meeting the prespecified primary efficacy
end point, these two phase III trials established that
[99mTc]tilmanocept plus blue dye identified at least one
SLN in a very high percentage of melanoma patients
(97.6 %), that [99mTc]tilmanocept identified more nodes
per patient than were visibly stained blue, and most
importantly that a substantial fraction of melanoma-con-
taining lymph nodes were radioactive but not visibly blue-
stained (20 % of all positive SLNs). [99mTc]Tilmanocept
had a favorable safety profile, with no serious adverse
events ascribed to the agent, and injections were well tol-
erated without any accompanying local anesthetics.
Although not specifically assessed as part of the trial
design, study investigators (all experienced melanoma
surgeons) perceived the [99mTc]tilmanocept lymphoscinti-
grams to be of high quality.
These phase III trials do not, however, allow for a direct
comparison between [99mTc]tilmanocept and other avail-
able radiopharmaceuticals for melanoma lymphatic
mapping. Potential advantages of its small molecular size
and the receptor-targeted nature of the mannose moieties in
[99mTc]tilmanocept include rapid transit from the primary
site to the SLN and selective accumulation in that node,
with limited pass-through to second-echelon nodes. A
radiopharmaceutical possessing these properties might be
particularly advantageous when the primary melanoma is
in close proximity to the sentinel node and/or for use in
conjunction with single positron emission computed
tomography (SPECT) imaging.22,23 In this regard, Fig. 2
shows a patient wherein the primary SLN is distinguished
within 20 min of the injection, and this SLN retained
[99mTc]tilmanocept 24 h later. Thus, this agent could be
particularly well suited for use in conjunction with SPECT
imaging and merits further evaluation in this setting.
The rigorous data obtained in these two phase III trials
strongly support [99mTc]tilmanocept as a safe and effective
agent for lymphatic mapping and intraoperative identifi-
cation of melanoma SLNs.
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